Notwithstanding promising clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable difficulty from pharmacy benefit managers. These https://deweyutib716467.life3dblog.com/40404405/company-s-vyndamax-faces-is-encountering-managed-care-organization-obstacles-the-review-at-reimbursement-battles